Company history

Shiseido began not as a cosmetics house but as a pharmacy. Arinobu Fukuhara — holder of Japan’s first pharmacist’s licence and formerly chief pharmacist of a naval hospital — left government service to practise the separation of prescribing from dispensing, and in September 1872 opened what he called Japan’s first Western-style dispensing pharmacy in Ginza, then the leading edge of the country’s modernization and the hub of its commercial traffic. Working as a private business rather than a state one, he built the pharmacy’s standing on guaranteeing quality to the doctors whose prescriptions it filled. The move into cosmetics came in January 1897 with the skin lotion Eudermine — “Shiseido’s red water” — into which Fukuhara carried the ingredient-control know-how learned in pharmaceuticals to set his product apart from imports.

The pharmacy turned into a maker over the next four decades. In 1915 the second president, Shinzo Fukuhara, steeped in European art and craft, devised the camellia (Hanatsubaki) trademark, giving the company a figurative identity that carried without words. Then came the design that would define Shiseido for a century. After the Great Kanto Earthquake of 1923 shattered the existing distribution network, Fukuhara turned the disorder into an opening: he rebuilt the wholesalers into “sales companies that handled Shiseido products alone,” and had the retailers who belonged to the chain hold the shares of those sales companies — a two-tier structure that bound every link of distribution to the maker by capital.

“I gave the chain stores shares in the sales company so that they would feel it was their own company, and tie their interests to ours,” Fukuhara later explained — a mechanism built to stop the discounting that a manufacturer normally cannot control. Incorporated as Shiseido in 1927 and completed in 1937 with the consumer club Hanatsubaki-kai layered on top, it was, in effect, a plan to command the whole flow from factory to consumer.

Listed on the Tokyo Stock Exchange in 1949, Shiseido spent the high-growth decades turning the pre-war design into postwar dominance. A 1952 “five-year leap plan” pushed planned investment into sales, advertising and manufacturing; the new Ofuna plant of 1959 gave it mass production of lotions and emulsions; and by 1964 Shiseido held the top share of Japan’s cosmetics market. Trade journals of the day framed the industry as a contest between Shiseido’s centralized chain system and rivals’ agency models, casting that centralization as the defining axis of the business.

By 1973 the machine was formidable: some 89 sales companies jointly funded with wholesalers, roughly sixteen thousand maker-led voluntary-chain stores beneath them, and effective command of cosmetics distribution — a marketing enterprise spoken of alongside “the Matsushita of home appliances.” So long as resale-price maintenance held, the three tiers of production, sales and advertising generated stable profit, and Shiseido stood beside the postwar carmakers and appliance giants as a representative consumer-goods company.

But maturity bred a structural flaw. As the 1980s began, consumers stopped buying by seasonal campaign and started choosing by age and locale, and the multi-product, small-lot strategy meant to answer that fragmentation, an executive later conceded, “in the end only increased inventory.” In 1983 president Yoshio Ohno admitted that Shiseido’s own chain-store policy had “overprotected” its retailers and sapped their self-reliance. The system that had manufactured dominance was now piling stock at the chain tier — and the work of dismantling what the founders had built was about to begin.

The dismantling came fast. In 1987 Shiseido recalled the stranded inventory from its sales companies in one sweep, and in 1988 collapsed 72 domestic sales companies into 15 — undoing, by its own hand, the network the founders had built. Then the legal ground gave way. When resale-price maintenance for cosmetics was abolished in 1997, discounting spread through the retail tier and the no-discount mechanism that had run since 1923 lost its premise; drugstore-based challengers grew on low prices, and the economic basis of the chain-store system vanished with a change in the law.

Shiseido’s answer was concentration. Entering the 2000s it carried roughly a hundred brands and its advertising was spread thin across all of them. Appointed president in 2005, Shinzo Maeda launched a “megabrand” strategy that poured advertising and promotion into a handful of core lines — Maquillage and Uno in 2005, Tsubaki in 2006, whose launch, fronted by twelve actresses and the group SMAP, became a landmark of Japanese consumer-goods advertising. A brand-manager system broke down the divisional silos, the megabrands reached more than 80% of domestic cosmetics sales, and the concentrated bet showed up, for a time, in the numbers.

Yet the profit structure broken in 1997 never returned, and by the 2010s the shift to digital channels was the next problem. In April 2014 Shiseido reached outside the company for Masahiko Uotani, a marketer who placed people at the centre of his management and ran a VISION 2020 built on investment in talent and on concentrating abroad in prestige. Following the 2010 purchase of Bare Escentuals, it bought the US clean-beauty house Drunk Elephant in 2019 and, that December, opened its Nasu plant — its first new domestic factory in 36 years. Uotani’s push crested in 2019 at sales of $9.2B (¥1tn), but much of that growth leaned on China and duty-free, leaving results hostage to geopolitics and, soon, to a pandemic.

In July 2021 Shiseido sold its personal-care business, in effect leaving the low-price market, and that December sold three US brands — Bare Minerals, Buxom and Laura Mercier — unwinding the businesses gathered in the 2010 Bare Escentuals deal. From the roughly hundred-brand portfolio of the Maeda years, it reorganized itself around skincare and prestige. To shed the domestic consumer brands it had carried since its founding was, on the eve of its 150th anniversary, a rewriting of what the company was: in the two-odd years from the 2019 Drunk Elephant purchase to the 2021 disposals, the answer to “who Shiseido sells to, and what” was rewritten.

Simplifying the portfolio lowered the complexity of brand-building and distribution, but it also handed results to outside forces. Shedding the high-volume, low-price lines meant giving up the buffer that had absorbed swings in demand and carried the fixed costs of domestic production and sales; prestige skincare left performance exposed to currency moves and to the buying of Chinese consumers. The shape the founders had bound together in 1923 was, in barely two years, swapped for a 2020s form concentrated on global prestige — and concentration narrowed the risk onto a single market.

That cost came due at the handover. In November 2022 Kentaro Fujiwara, who had run the China business, rose from managing executive to president with the China turnaround as his first charge. He bought the US skincare house DDG in February 2024 to reinforce prestige, and that September opened an early-retirement program at Shiseido Japan, shrinking the domestic workforce even as he leaned further on overseas brands. In its 2025 restructuring Shiseido wrote down the swollen goodwill from its Americas acquisitions in one stroke and absorbed a second straight year of losses — clearing the burden of past expansion by taking the loss in full. Whether 2025 becomes a foothold for the next growth, rather than the bottom of the fall, is a question the numbers have yet to answer.